Fig. 3From: Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trialThe tumor size before treatment, at baseline, and after treatment in patients with progression. The tumor growth kinetics ratio (TGKR) is also presentedBack to article page